Aquestive Therapeutics, Inc. (AQST) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
30Y Low13.0·High13.0
ROE
N/A
—
5yr avg: N/A
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low12.3·High12.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AQST Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aquestive Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $468M | $788M | $309M | $124M | $44M | $148M | $180M | $148M | $131M | — | — |
| Enterprise Value | $478M | $798M | $275M | $133M | $74M | $177M | $189M | $159M | $117M | — | — |
| P/E Ratio → | -6.20 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 10.50 | 17.69 | 5.36 | 2.45 | 0.92 | 2.91 | 3.93 | 2.81 | 1.94 | — | — |
| P/B Ratio | — | — | — | — | — | — | — | — | 12.95 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AQST EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 17.92 | 4.78 | 2.63 | 1.56 | 3.47 | 4.12 | 3.01 | 1.74 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
AQST Profitability
Margins and return-on-capital ratios measuring operating efficiency
Aquestive Therapeutics, Inc. earns an operating margin of -156.4%. Operating margins have compressed from -29.9% to -156.4% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.5% | 61.5% | 69.0% | 58.8% | 59.3% | 70.5% | 71.7% | 61.3% | 68.9% | 70.4% | 68.4% |
| Operating Margin | -156.4% | -156.4% | -53.5% | -29.9% | -88.2% | -68.2% | -93.6% | -100.1% | -72.6% | -0.2% | -1.6% |
| Net Profit Margin | -188.1% | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | -121.7% | -125.9% | -91.0% | -13.4% | -18.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | -3347.4% | -608.9% | — | — |
| ROA | -64.0% | -64.0% | -55.6% | -13.7% | -91.4% | -113.0% | -78.9% | -80.1% | -94.4% | -21.7% | -24.4% |
| ROIC | — | — | — | — | — | — | — | -5019.2% | — | -1.3% | — |
| ROCE | -71.3% | -71.3% | -50.6% | -53.3% | -146.1% | -84.8% | -84.3% | -92.5% | -119.8% | -0.4% | -3.0% |
AQST Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $10M ($131M total debt minus $121M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | 4.68 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 12.34 | 12.70 |
| Net Debt / Equity | — | — | — | — | — | — | — | — | -1.33 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | 7.63 | 9.67 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | 7.49 | — |
| Interest Coverage | -4.07 | -4.07 | -1.63 | -0.02 | -3.37 | -2.14 | -3.28 | -6.11 | -6.96 | -0.16 | -0.56 |
AQST Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Aquestive Therapeutics, Inc.'s current ratio of 3.14x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.24x to 3.14x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.14 | 3.14 | 4.68 | 2.24 | 1.01 | 2.15 | 2.11 | 3.68 | 2.25 | 1.83 | 2.16 |
| Quick Ratio | 3.01 | 3.01 | 4.36 | 1.87 | 0.86 | 1.97 | 2.00 | 3.53 | 2.09 | 1.57 | 1.89 |
| Cash Ratio | 2.55 | 2.55 | 3.79 | 1.30 | 0.69 | 1.28 | 1.51 | 2.66 | 1.84 | 1.13 | 0.85 |
| Asset Turnover | — | 0.28 | 0.57 | 0.88 | 0.84 | 0.82 | 0.73 | 0.67 | 0.78 | 1.55 | 1.31 |
| Inventory Turnover | 2.78 | 2.78 | 2.96 | 3.08 | 3.35 | 3.71 | 5.27 | 7.12 | 3.86 | 4.94 | 5.67 |
| Days Sales Outstanding | — | 145.55 | 46.57 | 61.13 | 36.01 | 87.03 | 55.37 | 91.10 | 35.08 | 33.70 | 76.24 |
AQST Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aquestive Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $122M | $87M | $61M | $49M | $38M | $34M | $25M | $21M | $20M | $25M |
Peer Comparison
Compare AQST with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AQSTYou | $468M | -6.2 | — | — | 61.5% | -156.4% | — | — | — |
 DARE | $32M | -1.8 | — | — | -137.5% | -1315.5% | -471.4% | — | — |
 AYTU | $19M | -1.1 | — | — | 69.0% | -11.8% | -58.1% | -33.5% | — |
 PRAX | $8B | -20.9 | — | — | — | — | -45.8% | -65.0% | — |
 LQDA | $6B | -88.8 | — | — | 91.6% | -32.5% | -113.0% | -102.5% | — |
 INVA | $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 SUPN | $3B | -65.3 | 45.1 | 55.6 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 COLL | $1B | 19.4 | 4.3 | 3.3 | 59.3% | 24.0% | 23.7% | 14.0% | 2.3 |
 PAHC | $1B | 26.8 | 12.7 | 30.9 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 PRGO | $1B | -1.0 | 7.1 | 9.8 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
AQST — Frequently Asked Questions
Quick answers to the most common questions about buying AQST stock.
What is Aquestive Therapeutics, Inc.'s P/E ratio?
Aquestive Therapeutics, Inc.'s current P/E ratio is -6.2x. This places it at the 50th percentile of its historical range.
Is AQST stock overvalued?
Based on historical data, Aquestive Therapeutics, Inc. is trading at a P/E of -6.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Aquestive Therapeutics, Inc.'s profit margins?
Aquestive Therapeutics, Inc. has 61.5% gross margin and -156.4% operating margin.